Surrozen (NASDAQ:SRZN) Cut to “Underweight” at JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of Surrozen (NASDAQ:SRZNGet Rating) from a neutral rating to an underweight rating in a research report sent to investors on Tuesday morning, The Fly reports.

SRZN has been the subject of several other research reports. Guggenheim lowered Surrozen from a buy rating to a neutral rating in a report on Friday, November 18th. Bank of America lowered shares of Surrozen from a neutral rating to an underperform rating in a research report on Wednesday, November 16th.

Surrozen Stock Performance

NASDAQ SRZN opened at $0.55 on Tuesday. The company has a market capitalization of $19.32 million, a PE ratio of -0.40 and a beta of -0.19. Surrozen has a 52-week low of $0.52 and a 52-week high of $9.50. The company has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $2.45.

Surrozen (NASDAQ:SRZNGet Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. As a group, analysts forecast that Surrozen will post -1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Several hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Surrozen during the 1st quarter worth about $377,000. FMR LLC purchased a new stake in shares of Surrozen in the second quarter worth about $744,000. Vanguard Group Inc. boosted its position in shares of Surrozen by 3.2% in the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company’s stock valued at $984,000 after acquiring an additional 15,299 shares during the period. Finally, Board of Trustees of The Leland Stanford Junior University grew its stake in Surrozen by 3,102.9% during the third quarter. Board of Trustees of The Leland Stanford Junior University now owns 781,960 shares of the company’s stock valued at $1,580,000 after acquiring an additional 757,546 shares in the last quarter. 65.68% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

(Get Rating)

Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Read More

The Fly logo

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.